HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Beauty Claims "Blur" Difference From Drugs As Cosmeceutical Market Grows

This article was originally published in The Tan Sheet

Executive Summary

Analysts agree cosmeceuticals remain a promising growth vehicle despite the notable regulatory questions the products can create.

You may also be interested in...

HBA Global Expo In Brief

Consumers picking products over medical procedures: Medical offices catering to client skin-care needs have seen a "flip" in revenue, with increased sales of skin-care products as well as injectables such as Botox rather than plastic surgery, according to Loretta Ciraldo, professor of dermatology at the University of Miami School of Medicine and principal of Dr. Loretta Skincare. Consumers have less discretionary income, and instead of coming in for a facelift they are opting for products to combat aging, she said Sept. 29 during an HBA Global Expo session entitled "The Future of Skincare: Finding Your Place in a Shifting Market." However, "there's a higher expectation on the part of the consumer" as they look for immediate results from products purchased at medical offices compared to products from traditional retail channels, Ciraldo noted

FDA Crackdown On Anti-Aging Imports Signals "Major Enforcement Initiative"

Increased scrutiny of anti-aging products with sunscreen ingredients entering the U.S. presages "a major enforcement initiative" against personal care product firms making noncompliant claims, according to a food and drug attorney who worked at FDA on import enforcement

Cosmeceutical Claims May Be Headed Into FDA's Radar

FDA under the Obama administration may cast a sharper eye on cosmeceuticals than the agency has in years past, according to Georgia C. Ravitz, a food and drug law lawyer at Arent Fox

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts